Medexus Pharmaceuticals Inc. (OTCMKTS:MEDXF) Short Interest Down 58.9% in April

Medexus Pharmaceuticals Inc. (OTCMKTS:MEDXF) was the target of a large drop in short interest in April. As of April 15th, there was short interest totalling 9,000 shares, a drop of 58.9% from the March 31st total of 21,900 shares. Based on an average trading volume of 26,300 shares, the short-interest ratio is currently 0.3 days.

Wall Street Analysts Forecast Growth

Separately, Raymond James reiterated a “strong-buy” rating on shares of Medexus Pharmaceuticals in a research note on Monday, February 3rd.

Medexus Pharmaceuticals Stock Down 2.5 %

OTCMKTS MEDXF opened at $1.93 on Monday. The firm’s fifty day moving average price is $1.79 and its 200 day moving average price is $2.03. Medexus Pharmaceuticals has a 12 month low of $1.10 and a 12 month high of $3.88.

About Medexus Pharmaceuticals

Medexus Pharmaceuticals Inc operates as a specialty pharmaceutical company in Canada and the United States. The company focuses on the therapeutic areas comprising oncology, hematology, rheumatology, auto-immune diseases, allergy, and dermatology. Its primary products are IXINITY, an intravenous recombinant factor IX therapeutic for use in patients 12 years of age or older with hemophilia B; Rasuvo and Metoject, a formulation of methotrexate designed to treat rheumatoid arthritis and other auto-immune diseases; Rupall, a prescription allergy medication; and Gleolan, an optical imaging agent indicated in patients with glioma as an adjunct for the visualization of malignant tissue during surgery.